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Abstract
All sexually active youth, whether obese or normal weight, should be offered counseling
regarding contraception and appropriate contraceptive methods. However, obese youth
who are sexually active may be less likely than their normal weight peers to use
contraceptives correctly. Methods of contraception for obese adolescents are reviewed in
this discussion. Combined oral contraceptives (COCs) and the contraceptive patch have
higher failure rates in obese versus normal weight females , though failure rates are lower
noted with barrier contraceptives. The risk for venous thrombosis is higher in obese
on COCs. Progestin-only pills and the levonorgestrel intrauterine system appear to
safe and effective methods in obese females. Depot-medroxyprogesterone acetate,
ring, and implants are also considered.

/?T Corres:por1de1ace: Professor Donald E Greydanus, MD, Pediatrics and Human Development, lVil'·'""''""
University College of Human Medicine, Pediatrics Program Director, Michigan State
Center for Medical Studies, Kalamazoo, MI 49008-1284 United States. Tel :
6474; E-mail : Greydanus@kcms.msu.edu
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Introduction
Sexually active adolescents whether chronically ill or not, should be offered contraception if
they are not willing to accept abstine11ce [1-7( Adolescents who are obese are at risk for
unwanted pregnancy with its well-known .risks and thus, should also be offered safe and
effective contraceptives. However, oyerv,rrifht or obese females are less likely to use
contraception than their normal weight peers, despite their higher risk for pregnancy-related
complications [8]. This chapter reyie~s)./Contraception in obese youth. In general,
contraception is much safer than risks pgse~ i1Jecause of obesity and pregnancy. Effective
methods that the clinician shotlld sp.~.~i~rrwsl~.qe combined oral contraceptives, mini-pills,
depo-medroxyprogesterone · .· ..aST~~S~~ . ~.~M-~'%:~.fWa~ ·... xing, implantable contraception, and
levonorgestrel intrauterine device (St!(!tapl~ l ). J?arrier methods are not generally effective in
youth.

Combined Ol"ijl ~pn~raceptives { cocs)
Females with obesity have some ~sgr~~~S~iTt~~a,~?'with COCs due to higher basal metabolic
rates, higher hepatic metapolisl.llofp!lZYt~t!~; ap.g dlJ.lg sequestration that is higher in adipose
tissue; however, effic;:tsyi~llighT~· t~~~ ~9!~gj"it111:>arrier methods [9-13]. There are over 145
brands of combineq ora}pontf~cep}ilf:es (~(JC~)usecithroughout the world, which generally
contain both syntheti? t)str()f.~l1)~~~ ~?'~~~S!i~~rg9S~tin. In the United States, birth control pill
brands are various .col11binatigns \5~tr~~SP. ·~Wi progestin. The usual estrogen is ethinyl
estradiol as the estl"()g~n, }ll()~g~ ~if:t!j"i/~~~p.gsi l.l~P mestranol. Various progestins are used
including norgestrel, Jevgpg~97~ttTbi! T~~~~g~~gl• •. diacetate, norethindrone acetate,
norethindrone, desogestrel, norgestill?-ate,y!lor;t~yn()drel, drospirenone, and gestodene (not
available in the US). The. ~ill ~~s P7?.~ s~~00~·tg. pe .a safe and effective contraceptive for
reproductive women - especi~lly .f or thg~e g~the .~dolescent age group. Thus, motivate
adolescent females who are obese ca11 ~till\:)T 7~S.Wml.gy~ to use the COC despite the reported
higher failure rates, mainly because •of tilt! ovep:~U efficacy of COCs and the known adverse
pregnancy outcomes.
Cunent recommendations are to beginwitllamonophasic pill, which has 30-35 meg of
estrogen and 0.15 to 1.5 mg of progestin; Af.Cai triphasic pill. Triphasic pills are also
recommended due to their low dose of~.~t.fg97n ~nd progestin. Careful monitoring and
selection of patients for birth control pill us.~ will reduce complications of the pill to a
considerable extent. Contraindications to oral contraception are reviewed in table 2. Sexually
active youth who are on combined oral contraceptives are advised to use condoms as well.
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Table 1. Contraceptive methods

L:orrmu11ea Oral Contraceptives (COCs)
£'1'1,nt•r<~t>Pn1rivP patch
C:fVJJrii-JlllllS (Progestin-only pills; POPs)
i

Depo-Provera® (Depo-medroxy-progesterone acetate
Lunelle® (estradiol cypionate and medroxyprogesterone acetate)
Norplant I (withdrawn from the US market in 2000)
Implanon (one rod system with etonogestrel)
Jadelle (Norplant II: two silastic rods with levonorgestrel)
vaginal ring (NuvaRing)
...... ¥•r•n Devices
Progestasert® IUD (with progesterone)
ParaGard® (Copper T380A IUD)
Mirena® (IUD with levonorgestrel)
barrier contraceptives
Cervical cap (Prentif Cavity-rim®)
Condoms (male)
Contraceptive sponge (vaginal)
Diaphragm
Female condom (Reality®)
Spermicides (vaginal)

o Evra Patch
patch provides contraceptive efficacy similar to COCs but may have an
risk for cardiovascular complications due to delivery of increased hormonal levels
to oral COCs [14]. As noted with the birth control pill, obesity (weight over 90 kg
~->vuu,~:.]) leads to reduced contraceptive efficacy, but still levels better than noted with
contraceptives [12,13,15,16]. Dennatitis can occur a,s well with patch technology.
with a history of skin allergy or exfoliative dermatological disorders may not be
candidates for the patch. There is also an increased incidence in breast symptoms,
most are reported to be mild or moderate [14,17]. Causes of increased risk
failure include having the patch on over seven days, patch detachment, and
to start a new patch after seven days of being off the patch.
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Contraindications to OCPs
The World Health Organization has .published a list of medical eligibility guidelines to
provide clinicians with guidelines for COC use in those with various chronic illnesses that
place users at increased risk of complications (see table 2) [18,19]. Those in WHO Category
1 have no restrictions to OCP use, whil~ thqse in Category 2 present with some increased
risk, though the risks of pregnancy exceed .them. Category 3 conditions have risks that are
further increased, such that the pill is not. used U[ll~ss risks for pregnancy are even higher and
no altemative contraceptive is available. Con~itJons found in Category 4 present risks that are
so high that OCPs are not prescribed.

Cardiovascular Complications
Research has indicated an increased risk of cardipvascg~ar complications in females on COCs
[7,20,21]. Obese females on birth control pill~hav~~e incr~~sed risk for pulmonary emboli,
thrombophlebitis, and vascular thromboses. • Spllle•i<~f~gi<::s • I1Qte a greater incidence of
myocardial infarction and subarachnoid ht!llorrg~~e a§. ;\VelL[21]. An absolute OCP
contraindication is a past history of ve11~~s t~·~~m~s~s • (~'G~ ..~11e the .risk of VT is more
significant for the adolescent or young ad'l.llttea[l ~l1?zi,.~ltgz81Jlll()§is. Significant obesity is a
VT risk factor andthe risk is i11creased inom.$[;$ . ~og~ser§[l2.,13,22].
Cardiovascular.deaths •. f[gm y<::eogs. ~~g .at1Ff~~1F81Jl~li9~~ip!lsil1 non-smoking females
aged 20-24 yearsis 2-6per million p~r;rear.'Ghereisia 3-6/ fold increased risk factor for VT
development in co~ .•·.us 7 r.~·· • i~I14. . tce?. >·st~~) f?f ~ i ~~ ieiR9<::r··••owith . desogestrel versus
levonorgestrel [7,20]. Thy VT.Gisk ii1; the g?~.Tral g~pulatip~ is Q..8 per 10,000 women per
year, 3-4 for those . on COSs, <li•pg 62l2.i fos D?l~~lt·~ ~hg. ~re pregnant or postpartum
[20,23,24]. Most who develop .veno~sthro~gpsisgp nothave identified VT risk factors.
Table 3 lists screening questions to use owe<::.l1 con§i~eripRgcPs for contraception. In general,
if there is no overt positive family history for VI', one does not need to screen for factor V
Leiden or other prothrombotic mutations.
Table 2. WHO medical eligibility categ()ries f()r OCPs. Used with permission (3]
Category one (no restrictions)
Antibiotics
Benign breast disease
Benign ovarian tumors
Cervical ectropion
Dysmenorrhea,
Endometriosis
Epilepsy
Family history of breast cancer
Gestational trophoblastic disease (benign or malignant)
Headaches (mild)
History of ectopic pregnancy or abortion (postabortion after first or second trimester),
History of gestational diabetes
Increased STD risk

Obesity and Contraception
Iron deficiency anemia
Irregular menstmal bleeding
Obesity
Ovarian or endometrial cancer
Past pelvic surgery
Pelvic inflammatory disease
Postpartum at or over 21 days
Thyroid disorders (as hypo/hyperthyroidism, simple goiter)
Varicose veins
Various infections :malaria, tuberculosis, others)
Sexually transmitted diseases
Viral hepatitis carrier
two (caution)
Cervical cancer
Diabetes mellitus (uncomplicated)
Headaches (severe and if they start after beginning OCPs)
Hype1tension at 140-159/100-109 mm Hg
Major surgery without prolonged immobilization
Migraine headaches without focal neurologic involvement.
Patients who have a hard time taking the OCP cmTectly:
drug or alchohol abuse
mental retardation
persistent history as poor OCP takers
severe psychiatric disorders
Sickle cell disease or sickle C disease
Undiagnosed breast mass
three (Usually no OCP given)
Gallbladder disease
Lactating (6 weeks to 6 months),
Less than 21 days postpa1tum
Medications that interfere with OCP efficacy
Undiagnosed abnormal vaginal/uterine bleeding.
four (OCP contraindicated)
Breast cancer
Cerebrovascular accident (active or history)
Complicated stmctural heart disease (with pulmonary hypertension, atrial fibrillation or history of
subacute bacterial endocarditis)
Coronary (or ischemic) heart disease (active or history)
Deep vein thrombosis or pulmonary embolism (active of history)
Diabetes mellitus (complicated with retinopathy, neuropathy, nephropathy)
Headaches (including migraine headaches) with focal neurologic symptoms
Hypertension (severe: ( 160+/11 0+ mm Hg or with vascular complications)
Lactation under 6 weeks postpartum
Liver disease (including liver cancer, benign hepatic adenoma, active viral hepatitis, severe
cirrhosis)
complicated
immobilization
the lower extremities and/or
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Table 3. Screening questions about personal/family history of thromboembolism

Is there a history of blood clots in legs or lungs in close family members, including
uncles and aunts?
2. Have any of your close family members been in the hospital for leg/lung blood clots?
3. Have you and/or close family members evertaking blood thinners?
4. What were the circumstances that led to blood clot (s), as for example while as a result of
traveling by airplane?
1.

The pill should be stopped before situations arise requiring prolonged bed rest as with some
surgeries. Hypertension and hyperlipidemia maybe complications of obesity. Blood pressure
should be regularly checked since it may rise i!1§0me patients.25 If there is a family or
personal history of hyperlidemia, OCPs m~.:r :·~tilli h~ prescribed if low-density lipoprotein
(LDL)levels remain < 160 mg/dl andtriglyceridf)s < 250. COCs are not recommended for
adolescents (obese or not) if they have (;gp_gestiy~}ieart failure, cardiac shunts, or low output
heart disorders.5,26

Diabetes Mellitus
Diabetes mellitus may be a .complic~~ioi} bf ~t· . oc.cl1r incidental of obesity. Current evidence
suggests that combined oral contr~p~ptiye~ ~r~ safe for obese females with well-controlled
diabetes mellitus typesl and2[12]. 88ys do ngtworsen the metabolic status in diabetic
females [12,13,27]. (Sareisn~eded ~79~~se. ofsoncernover worsening metabolic status due
to progestins and ·. increa~e~· i.risk<f~~· t1lr.()ZSl~g.t~n~~~~c events due to estrogen [28]. COCs
should not be offered if ·they are Ae\ poor llletabolic control or have hypertension,
nephropathy, or retinopathy. Other C()ntr~cTptive methods that are safe and effective in
females with diabetes include progestin,_o!llypil1s .agd the intrauterine device (IUD) [13].
There may be an increase in recurrent, treatirient'",resistant vaginal yeast infections in diabetic
youth with an IUD [28]. The use of degg~~7grpX)'Pr9gesterone acetate or levonorgestrel
implant may worsen the metabolic status in.qiAPf!tic; fy]Jlales.

Migraine Headaches
Caution is advised when prescribing the birth control pill to an individual with a history of
migraine headaches and the COC should be stopped if the migraine aura or headache pattern
worsen on COCs [1-4]. If the individual has a history of severe migraines or migraines with
prolonged auras (as with the hemiplegic or ophthalmoplegic types) the pill should not be
given. If the migraine headache and/or the aura worsen while on the pill, it should be stopped
immediately. Careful monitoring is advised when placing women with migraines on the pill.
It is not known if obesity presents a greater risk for migraine-related cerebrovascular
accidents that may be increased by the COCs or patch.
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Conditions
"""'"'" with active liver disease should not be placed on OCPs. The effect of obesity-related
(nonalcoholic steatohepatitis) on COCs not clear at this time. Youth with obesity may
risk for depression and no obesity-related complications with SSRis are repmied.
antidepressants can reduce estrogen levels with increased BTB but not reduced
'""'"'""'•" ·'~ efficacy. St. John's wart is used to treat depression and can lead to increased
bleeding and anecdotal reports of reduced OC efficacy [ 1-4]. Some females
obesity are at increased risk for fungal infections and some anti-fungal agents are potent
enzyme inducers with resultant decreased contraceptive efficacy; these agents include
vin, ketoconazole and itraconazole. Other drugs can interfere with contraceptive
such as rifampin. Table 4 lists management principles for miscellaneous side effects

estin-only Pills (POPs) (Mini-Pills)
contain 0.35 mg ofnorethindrone (Micronor®; Nor-Q.D®) and0.075mg ofnorgestrel
. Obesity may be associated with reduced contraceptive efficacy [13]. POPs are.
used in those individuals having disorders where estrogen maybe contraindicated as sickle cell anemia, cyanotic hea1i disease, severe hypertension, diabetes mellitus, and
(see table 2). Some clinicians have not recommended the mini-pill for teenagers
of its increased pregnancy rate as well as frequent breakthrough bleeding and
enc>rr11ea noted in some females on the mini-pill [1-4]. POPs are avoided in those with a
of ectopic pregnancy and those taking certain medications (as anticonvulsants,
vin and rifampin). There is no increase in VT in obese females on progestin-only
12,13].
Table 4. Management of some oral contraceptive related problems

monilial vaginitis

Anti-acne measures and medications
Anti-fungal agents (as fluconazole); persistent infections:
Look for underlying factors, as diabetes mellitus, other
endocrinopathies, use of antibiotics, infected male genital
tract, others. Oral nystatin may reduce gastrointestinal
reservoir; use anti-fungal agents for a protracted period of
treatment.
Usually a transient condition; ensure patient is taking the pill
each day; higher estrogen pill or supplemental estrogen may
help; evaluate for .underlying pathology
COCs are not teratogenic but should be stopped as ~~..,··~ ~...,. > • ,., •..
the pregnancy is identified.
Use a lower
11
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Depot-Medroxyprogesterone Acetate (DMPA)
The main injectable contraceptive ayail~ple (inthe US is depomedroxy-progesterone acetate
(Depo-Provera®). It is given in a dose o£150 mg intramuscularly every three months and
DMPA has a better contraceptiv~ ·Tffi~~.9~i thaJ1)he COC with a failure rate of 0.3%. No
decreased contraceptive efficacy i s ggted igobese females versus normal weight females
[ 13]. Its mechanism of actioninclmles an induction of a low FSH/LH level, low LH surge,
production of an atrophic eq49l1J..#tzi~lc~?ii al,le>thiclcening of the cervical mucus. Side effects
include irregular menses, amenq~·~Ta,', a:n&.• . 1J~east tenderness, weight gain (with bloating),
decrease in bone density, 4&crea~& R~i~~.p4-d(msity ·lipoprotein levels, and some behavioral
changes such as irritability anqgepre§~~Rn.
It is useful where a hi~~ly>rrtf:&:!iYR :?gtr~ctptive is needed and where the side effects of
an estrogen-type contraceptiv&frustp&iavoiged. Thus, it has been used for individuals with
cyanotic heart disease, §if~t-c~.}} ~g5t1~.~' t~yp~nbophlebitis, and others. Internationally,
psychotic and retarded i11divig~~ls w~q are ~j risk for pregnancy have been prescribed this
injectable ·contraceetiye. I~ . i~ Bqg~.~gt1·eg. 5q lJt .a .very effective hormonal contraceptive for
obese females, despiteit~e }"e~qged:•.9~~ggtJigbodycomposition towards fatness and central
redistributiono{fat follq'\ingitsuse.·W\''C .... \)F . '
Another .inject<J:1Jle• ~811~apept~'\fe•Y J::.,~ellt~ (5 mg estradiol cypionate and 25 mg
medroxyprogesterone a~etate I.NfP~tC]),'\as approved by the FDA in 2000. Estrogen is
added to allow abettermenstru(ltperipgi ~~)'t~; than seen with Depo-Provera. Less weight
gain is noted and overall adverse •Fe{fects life similar to COCs [29]. Lunelle® is given
intramuscularly every 28-30 daysaggifh~~ i ~:~ip~contraceptive efficacy rate [30]. One study
noted that there was a weight gain o£0,9 k~lto 1.8 kg if the female weighed under 68 kg
versus a weight gain of 1.4 to 3.6 J,cg if'pver 68 kilograms [30]. There is no overt
contraindication in females with obesity;.

Emergency Contraceptives
Emergency contraceptives (EC) are . ~ni611& !he ··)11()St controversial and under prescribed
contraceptive methods (seee table 5)[31}.• ~1Je~i~is >not a contraindication to use of ECs.
Anti-emetics can be given to preventthe tr7quentoccurrence of nausea and emesis that
occurs with high dose estrogen; th~s,ap ~1ltiefrT~i9.s~quld be taken an hour before taking
these pills. In 1999, the US Food a11qi?rug~9mini§tration (FDA) approved of Plan B®, a
progestin-only method with two tables of O.'Zt; mg pflevonorgestrel. The first tablet is taken
immediately and the second tablet is takent'N()hol1rs later. Because Plan B® contains no
estrogen, nausea and vomiting is uncomn1:on.and there is no need to obtain a pregnancy test
before adrninistation. Thus, Plan B may be better tolerated than those with estrogen [32].
Though the official recommendation is thatthey must be used within three days of coitus,
they may be effective in pregnancy prevention within five days.
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Table 5. Emergency contraceptives

Ovral® : 2 tablets followed by 2 tables in 12 hours
Lo/Ovral®, Nordette® or Levien®: 4 tabs and 4 more in 12 hours
Plan B®: levonorgestrel, 0.75mg followed by 0.75 mg in 12 hours
Preven® Emergency Contraceptive Kit
Ovrette®: 20 tabs and 20 more in 12 hours
: 4 tabs, and 4 more in 12 hours
TriPhasil® or Tri-Levlen®

ng® (Vaginal Ring)
is a soft, flexible, transparent vaginal ring made of a ethylene vinyl acetate copolymer; it
outer diameter of 54 mm and a cross-section of 4 mm [2,4] . There are two steroid
cores that provide a daily bmmonal release of 15 meg of ethinyl estradiol and 120
of etonogestrel (an active metabolite of desogestrel) [30,33]. Side effects include
withdrawal bleeding, vaginal discomfort, nausea, headache, nervousness, acne,
tenderness, leukon hea, reduced libido, and slight weight gain. Thereis an increased
of thrombotic diseases [34]. There is usually less inegular bleeding than seen with
. Extremely overt weight females may have trouble inserting the ring. Obesity itself
not effect the contraceptive efficacy of the NuvaRing and it is considered as one of the
effective hormonal contraceptive methods for obese females.

was the first implantable contraceptive developed and was very effective as a
It contains six silastic levonorgestrel-containing rods; however, it was
from the United States market in 2000 [2,4]. The Jadelle® implant (Norplant II)
two silastic rods with levonorgestrel and Implanon® contains one rod (vinyl
acetate polymer) with etonogestrel [7,35]. Both Jadelle® and Implanon® are
by the FDA for three years and are not contraindicated in obesity, though both may
some weight gain .. Though obese females have been found to have lower serum
levels, there is no reduced efficacy noted with Implanon in obese female [13,36].

rine Device (IUD)
three IUDs which currently are used in the United States: Progestasert IUD®, the
(Copper T380A) and the Mirena IUD [2,4,37-39]. Previous controversial IUD
pelvic inflammatory disease (PID) have limited its application to aqolpscents.
the IUD is an excellent contraceptive method with no contraindicatio1l .• il1/ ?bese
The Mirena® IUD (Levonorgestrel-containing IUD; LNG-IUD) was FDA-aPPfc?s®~
for five years and contraindications are active PID, prosthetic heartvalves, histql)'()f
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subacute bacterial· endocarditis, and distorted uterine cavity. The most common side effect is
menstrual bleeding; there is increased bleeding and spotting during the first 3-6 months after
insertion that usually decreases after this time. Obese females have an increased incidence of
dysfunctional uterine bleeding and ~ndometrial hyperplasia, making the Mirena IUD a good
contraceptive choice for obese fem1:1,)es .ueeding contraception [12]. No reduced contraceptive
efficacy has been noted because of pbe~ity [13 ,40]. In diabetic patients, an increase in vaginal
yeast infections should be taken underconsideration.

Conclusions
Contraceptive efficacy is reduc~di~• ()~~~~fet~al~s oil the combined oral contraceptive and
the contraceptive patch; ho\V.~v;r, Jfe { ef~~~c~ is still above that noted with banier
contraceptives. COCs are safewi~f ~Rs~.~ ffl1lales \Vith diabetes mellitus if they are in good
control and do . nothave Tiepftfop~th~, x:~in~pa~hy, n~11ropathy, or hype11ension. Progestinonly pills are safe in obfse :~111~lr~ Rl!t i~Scr:a~~d contraceptive efficacy is noted in all
females on this c~Tit~~s~gtiv~ p:u::teg~· ~l:>ssi!)' i~ 11~t a contraindication to use of depomedroxyproge~teron~ ac~tatf:, ~UJ.:)• l:l.Tig jTI~f~X~~ip,~l . l"il19· · The mini-pill and levonorgestrel
IUD may be the safest for obesefemal~s l1~f:di11gp8ntraception [ 12].
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